Asset profile
THRV-1268
Small molecule
Evidence outlook · lead readout
NCT07186946 · Heart Failure
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07186946: This was a randomized, mostly double-blind, placebo-controlled study, which is a reasonable design for an early safety trial, but it enrolled only 16 people and tracked only a safety endpoint, and results are not yet posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.